Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
+ 1018 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 373 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
+ 147 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Locations: - Palo Verde Hematology Oncology — Glendale, Arizona
- Mayo Clinic Building - Phoenix — Phoenix, Arizona
- Mayo Clinic Hospital — Phoenix, Arizona
+ 125 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Los Angeles General Medical Center — Los Angeles, California
+ 98 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Locations: - Ironwood Cancer and Research Center — Chandler, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Oncology Associates PC NAHOA — Prescott, Arizona
+ 67 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Banner-University Medical Center Phoenix — Phoenix, Arizona
+ 57 more sites in the U.S.
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Locations: - Clinical Study Site — Goodyear, Arizona
- Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Beverly Hills, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Locations: - Los Angeles Hematology Oncology Medical Group ( Site 0084) — Los Angeles, California
- University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087) — Fort Collins, Colorado
- Rocky Mountain Cancer Centers (RMCC) ( Site 8000) — Lone Tree, Colorado
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Locations: - Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
- Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Locations: - City of Hope — Arcadia, California
- Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
+ 15 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.